Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 4/20 | 0.33 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30781373 | 0.82 | STS (0.36) | STSMEN1KMT2ANR1H2KDM4E | |
| SCHEMBL27153718 | 0.77 | ERBB2 (0.32) | STSMEN1KMT2AMMP13ADAM17 | |
| SCHEMBL24438534 | 0.76 | NR1H2 (0.48) | MEN1KMT2ANR1H2RORCMAPT | |
| SCHEMBL29126202 | 0.76 | NR1H2 (0.48) | MEN1KMT2ANR1H2RORCMAPT | |
| SCHEMBL12526132 | 0.76 | NR1H2 (0.48) | MEN1KMT2ANR1H2RORCMAPT | |
| SCHEMBL21846801 | 0.75 | STS (0.38) | STSMEN1KMT2ANR1H2CNR1 | |
| SCHEMBL31076409 | 0.74 | RORC (0.39) | MEN1KMT2ANR1H2RORCCNR1 | |
| SCHEMBL31076338 | 0.72 | RORC (0.43) | STSNR1H2RORCMAPT | |
| SCHEMBL28484617 | 0.72 | NR1H2 (0.40) | MEN1KMT2ANR1H2RORCMAPT | |
| SCHEMBL28476213 | 0.72 | NR1H2 (0.40) | MEN1KMT2ANR1H2RORCMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084829-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084829-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| WO-2020068600-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020068600-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200095260-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200095260-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095260-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | STS 2095/4885MEN1 3693/4885KMT2A 2614/4885 |
| US-11084829-B2 | Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof | USP7, SENP7, USP8 | STS 2095/4885MEN1 3693/4885KMT2A 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.